Paradigm Biocapital Advisors LP Zentalis Pharmaceuticals, Inc. Transaction History

Paradigm Biocapital Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$10.83 - $16.49 $5.9 Million - $8.99 Million	544,917 Added 136.23%	944,917 $14.9 Million
Q4 2023 Feb 14, 2024	BUY	$9.84 - $20.13 $3.94 Million - $8.05 Million	400,000 New	400,000 $6.06 Million
Q2 2022 Aug 15, 2022	SELL	$17.91 - $52.25 $5.15 Million - $15 Million	-287,577 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$41.58 - $80.89 $534,594 - $1.04 Million	-12,857 Reduced 4.28%	287,577 $13.3 Million
Q4 2021 Feb 14, 2022	BUY	$66.92 - $84.79 $20.1 Million - $25.5 Million	300,434 New	300,434 $25.3 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.